Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 62, Issue 5, 2015, Pages 759-765

  Lerman, Daniel M ^a,b   Monument, Michael J ^a,b   Mcilvaine, Elizabeth ^c   Liu, Xiao Qiong ^d   Huang, Dali ^d   Monovich, Laura ^e   Beeler, Natalie ^e   Gorlick, Richard G ^f   Marina, Neyssa M ^g   Womer, Richard B ^h   Bridge, Julia A ^d   Krailo, Mark D ^c   Randall, R Lor ^a,b   Lessnick, Stephen L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

^e THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarker; Ewing sarcoma; Outcomes; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PROTEIN P53; VINCRISTINE; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; DNA SEQUENCE; EWING SARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; YOUNG ADULT; BONE TUMOR; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENETICS; MORTALITY; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; BIOMARKERS, TUMOR; BONE NEOPLASMS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; SARCOMA, EWING; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925444134     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25340     Document Type: Article

References (49)

1. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011.
2. Wang CC, Schulz MD. Ewing's sarcoma: A study of fifty cases treated at the Massachusetts General Hospital, 1930-1952 inclusive. N Engl J Med 1953; 248:571-576.
3. Dahlin DC, Coventry MB, Scanlon PW. Ewing's sarcoma. A critical analysis of 165 cases. J Bone Joint Surg Ame 1961; 43-A:185-192.
4. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 2012; 30:4148-4154.
5. Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, Baruchel S, Chuba PJ, Sailer SL, Brown K, Ranganathan S, Marina N. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT 0006 1893. Pediatr Blood Cancer 2013; 60:409-414.
6. Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir GM. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet Cytogenet 1984; 12:1-19.
7. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229-238.
8. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 1984; 311:584-585.
9. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-165.
10. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006; 4:851-859.
11. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006; 9:405-416.
12. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995; 11:1049-1054.
13. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Thomas G, Gadner H. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7:429-437.
14. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239-247.
15. Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997; 31:9-16.
16. Thompson AD, Teitell MA, Arvand A, Denny CT. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 1999; 18:5506-5513.
17. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993; 90:5752-5756.
18. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1:393-401.
19. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001; 20:6731-6741.
20. Crawford LV, Pim DC, Gurney EG, Goodfellow P, Taylor-Papadimitriou J. Detection of a common feature in several human tumor cell lines-a 53, 000-dalton protein. Proc Natl Acad Sci USA 1981; 78:41-45.
21. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-83.
22. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12:3008-3019.
23. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88:593-602.
24. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-5014.
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-1245.
26. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
27. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-707.
28. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-330.
29. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: One gene-two products-two pathways. Trends Biochem Sci 1998; 23:291-296.
30. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: A highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23:548-558.
31. Amir G, Issakov J, Meller I, Sucher E, Peyser A, Cohen IJ, Yaniv I, Ben Arush MW, Tavori U, Kollender Y, Ron N, Peylan-Ramu N. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: Correlation with clinical outcome. Hum Pathol 2002; 33:170-174.
32. Mangham DC, Cannon A, Li XQ, Komiya S, Gebhardt MC, Springfield DS, Rosenberg AE, Mankin HJ. P53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event. Clin Mol Pathol 1995; 48:M79-M82.
33. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001; 81:803-814.
34. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH, Ladanyi M. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000; 89:793-799.
35. Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, Grimer RJ. Overexpression of p53 protein in primary Ewing's sarcoma of bone: Relationship to tumour stage, response and prognosis. Br J Cancer 1999; 79:1185-1189.
36. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000; 89:783-792.
37. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Farinas S, Picci P, Llombart-Bosch A. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 2011; 128:1139-1150.
38. Park YK, Chi SG, Kim YW, Park HR, Unni KK. Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma. Oncol Rep 1999; 6:1261-1266.
39. Brownhill SC, Taylor C, Burchill SA. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 2007; 96:1914-1923.
40. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Hoboken, NJ: J Wiley; 2002. 439p.
41. Patino-Garcia A, Sierrasesumaga L. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet 1997; 98:50-55.
42. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000; 120:91-98.
43. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999; 14:1-8.
44. Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 2010; 116:1964-1973.
45. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88:1456-1466.
46. Yang Y, Zhen T, Zhang F, Dai S, Kang L, Liang Y, Xue L, Han A. P53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour. J Clin Pathol 2013.
47. Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER. Biomarkers in Ewing Sarcoma: The Promise and challenge of personalized medicine. A report from the Children's Oncology Group. Front Oncol 2013; 3:141.
48. Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL. A Decade in Banking Ewing Sarcoma: A report from the Children's Oncology Group. Front Oncol 2013; 3:57.
49. Hodgson DR, Whittaker RD, Herath A, Amakye D, Clack G. Biomarkers in oncology drug development. Mol Oncol 2009; 3:24-32.